Skip to content

Safety Study of Rufinamide Given as an add-on Therapy to Treat Patients With Seizures

A Double-Blind, Placebo-Controlled, Parallel-Group Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures

Status
Withdrawn
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04558580
Enrollment
0
Registered
2020-09-22
Start date
2006-04-30
Completion date
2008-12-31
Last updated
2020-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractory Partial Seizures

Keywords

Seizure, Seizures, Epilepsy

Brief summary

This study will evaluate the efficacy and safety of Rufinamide in reducing seizure frequency in subjects with partial seizures not fully controlled despite treatment with 1 to 3 concomitant antiepileptic drugs.

Interventions

Rufinamide

Sponsors

University of South Alabama
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
12 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Male and Female patients between 12 and 80 years of age * Dx of epilepsy with partial onset seizures woth or woth out secondarily generalized seizures * Non controlled partial seizures despite treatment with 2 different AEDs for at least 2 years * must have 6 seizures during baseline * current treatment with maximum of 3 AEDs * stable dose of AED(s)for at least 1 month * if patient has VNS, must have been implanted 6 months prior to randomization

Exclusion criteria

* Participation in any investigational product for at least 1 month prior to visit 1 * Presence of non-motor simple partial seizures only * presence of generalized epilepsies * Evidence of clinically significant disease * Clinically significant ECG * Psychogenic seizure in previous year * History of drug/alcohol abuse * History of suicide attempt * Multiple drug allergies * Concomitant felbamate use * Need for frequent rescue benzodiazepines * Concomitant use of vigabatrin * All patients diagnosed with congenital short QT syndrome

Design outcomes

Primary

MeasureTime frame
Percentage change in total partial seizure frequency from baseline.22 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026